α1-Adrenergic receptors mediate the locomotor response to systemic administration of (±)-3,4-methylenedioxymethamphetamine (MDMA) in rats

Pharmacology Biochemistry and Behavior

Volumn 86, Issue 4, 2007, Pages 622-630

  Selken, Jennifer ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

1 Adrenoceptor; Locomotor activity; MDMA; Prazosin; Rats

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALPHA 1 ADRENERGIC RECEPTOR; AMPHETAMINE; PRAZOSIN; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DEXAMPHETAMINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG POTENCY; LOCOMOTION; MALE; MICROINJECTION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; VENTRAL TEGMENTUM; ANIMAL; DRUG EFFECT; DRUG INTERACTION; MOTOR ACTIVITY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DEXTROAMPHETAMINE; DRUG INTERACTIONS; MALE; MICROINJECTIONS; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PRAZOSIN; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC, ALPHA-1; VENTRAL TEGMENTAL AREA;

EID: 34249718993     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.02.006     Document Type: Article

References (53)

1. Anderson III G.M., Braun G., Braun U., Nichols D.E., and Shulgin A.T. Absolute configuration and psychotomimetic activity. NIDA Res Monogr (1978) 8-15
2. Arnt J. Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of (+)-amphetamine. Eur J Pharmacol 283 (1995) 55-62
3. Bankson M.G., and Cunningham K.A. Pharmacological studies of the acute effects of (+)-3,4- methylenedioxymethamphetamine on locomotor activity: role of 5- HT(1B/1D) and 5-HT(2) receptors. Neuropsychopharmacology 26 (2002) 40-52
4. Blanc G., Trovero F., Vezina P., Herve D., Godeheu A.M., Glowinski J., et al. Blockade of prefronto-cortical alpha 1-adrenergic receptors prevents locomotor hyperactivity induced by subcortical (+)-amphetamine injection. Eur J Neurosci 6 (1994) 293-298
5. Bozarth M.A., and Wise R.A. Intracranial self-administration of morphine into the ventral tegmental area in rats. Life Sci 28 (1981) 551-555
6. Bradshaw C.M., Pun R.Y., Slater N.T., and Szabadi E. Comparison of the effects of methoxamine with those of noradrenaline and phenylephrine on single cerebral cortical neurones. Br J Pharmacol 73 (1981) 47-54
7. Bradshaw C.M., Stoker M.J., and Szabadi E. Comparison of the neuronal responses to 5-hydroxytryptamine, noradrenaline and phenylephrine in the cerebral cortex: effects of haloperidol and methysergide. Neuropharmacology 22 (1983) 677-685
8. Bylund D.B., Eikenberg C., Hieble J.P., Langer Sz., Lefkowitz R.J., Minneman K.P., et al. International Union of Pharmacology: nomenclature of adrenoreceptors. Pharmacol Rev 46 (1994) 121-128
9. Callaway C.W., and Geyer M.A. Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat. Eur J Pharmacol 214 (1992) 45-51
10. Callaway C.W., and Geyer M.A. Tolerance and cross-tolerance to the activating effects of 3,4- methylenedioxymethamphetamine and a 5-hydroxytryptamine1B agonist. J Pharmacol Exp Ther 263 (1992) 318-326
11. Callaway C.W., Rempel N., Peng R.Y., and Geyer M.A. Serotonin 5-HT1-like receptors mediate hyperactivity in rats induced by 3,4-methylenedioxymethamphetamine. Neuropsychopharmacology 7 (1992) 113-127
12. Callaway C.W., Wing L.L., and Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4- methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther 254 (1990) 456-464
13. Cole J.C., and Sumnall H.R. Altered states: the clinical effects of Ecstasy. Pharmacol Ther 98 (2003) 35-58
14. Darracq L., Blanc G., Glowinski J., and Tassin J.P. Importance of the noradrenaline-dopamine coupling in the locomotor activating effects of (+)-amphetamine. J Neurosci 18 (1998) 2729-2739
15. Dickinson S.L., Gadie B., and Tulloch I.F. Alpha 1- and alpha 2-adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by (+)-amphetamine and apomorphine in the rat. Psychopharmacology (Berlin) 96 (1988) 521-527
16. Drouin C., Blanc G., Trovero F., Glowinski J., and Tassin J.P. Cortical alpha 1-adrenergic regulation of acute and sensitized morphine locomotor effects. NeuroReport 12 (2001) 3483-3486
17. Drouin C., Blanc G., Villegier A.S., Glowinski J., and Tassin J.P. Critical role of alpha1-adrenergic receptors in acute and sensitized locomotor effects of (+)-amphetamine, cocaine, and GBR 12783: influence of preexposure conditions and pharmacological characteristics. Synapse 43 (2002) 51-61
18. Drouin C., Darracq L., Trovero F., Blanc G., Glowinski J., Cotecchia S., et al. Alpha1b-adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J Neurosci 22 (2002) 2873-2884
19. Fantegrossi W.E., Kiessel C.L., Leach P.T., Martin C.V., Karabenick R.L., Chen X., et al. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology (Berlin) 173 (2004) 270-277
20. Fitzgerald J.L., and Reid J.J. Interactions of methylenedioxymethamphetamine with monoamine transmitter release mechanisms in rat brain slices. Naunyn-Schmiedeberg's Arch Pharmacol 347 (1993) 313-323
21. Geyer M.A., Russo P.V., Segal D.S., and Kuczenski R. Effects of apomorphine and amphetamine on patterns of locomotor and investigatory behavior in rats. Pharmacol Biochem Behav 28 (1987) 393-399
22. Gold L.H., Koob G.F., and Geyer M.A. Stimulant and hallucinogenic behavioral profiles of 3,4- methylenedioxymethamphetamine and N-ethyl-3,4-methylenedioxyamphetamine in rats. J Pharmacol Exp Ther 247 (1988) 547-555
23. Gold L.H., Hubner C.B., and Koob G.F. A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA. Psychopharmacology (Berlin) 99 (1989) 40-47
24. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol Rev 55 (2003) 463-508
25. Grenhoff J., Nisell M., Ferre S., Aston-Jones G., and Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J Neural Transm Gen Sect 93 (1993) 11-25
26. 1-adrenergic effects on dopamine neurons recorded intracellularly in the rat midrain slice. Eur J Neurosci 7 (1995) 1707-1713
27. Gresch P.J., Sved A.F., Zigmond M.J., and Finlay J.M. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J Neurochem 65 (1995) 111-116
28. Harkin A., Morris K., Kelly J.P., O'Donnell J.M., and Leonard B.E. Modulation of MK-801-induced behaviour by noradrenergic agents in mice. Psychopharmacology (Berlin) 154 (2001) 177-188
29. Johnson M.P., Conarty P.F., and Nichols D.E. [3H]monoamine releasing and uptake inhibition properties of 3,4- methylenedioxymethamphetamine and p-chloroamphetamine analogues. Eur J Pharmacol 200 (1991) 9-16
30. Karreman M., and Moghaddam B. The prefrontal cortex regulates the basal release of dopamine in the limbic striatum: an effect mediated by ventral tegmental area. J Neurochem 66 (1996) 589-598
31. Karreman M., Westerink B.H., and Moghaddam B. Excitatory amino acid receptors in the ventral tegmental area regulate dopamine release in the ventral striatum. J Neurochem 67 (1996) 601-607
32. Kehne J.H., Ketteler H.J., McCloskey T.C., Sullivan C.K., Dudley M.W., and Schmidt C.J. Effects of the selective 5-HT2A receptor antagonist MDL 100,907 on MDMA-induced locomotor stimulation in rats. Neuropsychopharmacology 15 (1996) 116-124
33. Marek G.J., and Aghajanian G.K. 5-HT2A receptor or alpha1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex. Eur J Pharmacol 367 (1999) 197-206
34. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., and Svensson T.H. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol 309 (1996) 1-11
35. McCreary A.C., Bankson M.G., and Cunningham K.A. Pharmacological studies of the acute and chronic effects of (+)-3, 4-methylenedioxymethamphetamine on locomotor activity: role of 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B/1D) receptors. J Pharmacol Exp Ther 290 (1999) 965-973
36. McNamara M.G., Kelly J.P., and Leonard B.E. Some behavioural and neurochemical aspects of subacute (+/-)3,4-methylenedioxymethamphetamine administration in rats. Pharmacol Biochem Behav 52 (1995) 479-484
37. Nash J.F., Roth B.L., Brodkin J.D., Nichols D.E., and Gudelsky G.A. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors. Neurosci Lett 177 (1994) 111-115
38. Nichols D.E., Hoffman A.J., Oberlender R.A., Jacob III P., and Shulgin A.T. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 29 (1986) 2009-2015
39. Pan W.H., Sung J.C., and Fuh S.M. Locally application of amphetamine into the ventral tegmental area enhances dopamine release in the nucleus accumbens and the medial prefrontal cortex through noradrenergic neurotransmission. J Pharmacol Exp Ther 278 (1996) 725-731
40. Pozzi L., Invernizzi R., Cervo L., Vellebuona F., and Samanin R. Evidence that extracellular concentrations of dopamine are regulated by noradrenergic neurons in the frontal cortex of rats. J Neurochem 63 (1994) 195-200
41. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I., et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39 (2001) 32-41
42. Rothman R.B., Partilla J.S., Baumann M.H., Dersch C.M., Carroll F.I., and Rice K.C. Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse 35 (2000) 222-227
43. Shi W.X., Pun C.L., Zhang X.X., Jones M.D., and Bunney B.S. Dual effects of (+)-amphetamine on dopamine neurons mediated by dopamine and nondopamine receptors. J Neurosci 20 (2000) 3504-3511
44. Simantov R. Multiple molecular and neuropharmacological effects of MDMA (Ecstasy). Life Sci 74 (2004) 803-814
45. Smialowska M., Gastol-Lewinska L., and Tokarski K. The role of alpha-1 adrenergic receptors in the stimulating effect of neuropeptide Y (NPY) on rat behavioural activity. Neuropeptides 26 (1994) 225-232
46. Snoddy A.M., and Tessel R.E. Prazosin: effect on psychomotor-stimulant cues and locomotor activity in mice. Eur J Pharmacol 116 (1985) 221-228
47. Sprague J.E., Banks M.L., Cook V.J., and Mills E.M. Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J Pharmacol Exp Ther 305 (2003) 159-166
48. Steele T.D., Nichols D.E., and Yim G.K. Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochem Pharmacol 36 (1987) 2297-2303
49. Strote J., Lee J.E., and Wechsler H. Increasing MDMA use among college students: results of a national survey. J Adolesc Health 30 (2002) 64-72
50. Svensson T.H., Mathe J.M., Andersson J.L., Nomikos G.G., Hildebrand B.E., and Marcus M. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism [corrected]. J Clin Psychopharmacol 15 (1995) 11S-18S
51. Treit D., and Fundytus M. Thigmotaxis as a test for anxiolytic activity in rats. Pharmacol Biochem Behav 31 (1988) 959-962
52. Vollenweider F.X., Liechti M.E., Gamma A., Greer G., and Geyer M. Acute psychological and neurophysiological effects of MDMA in humans. J Psychoact Drugs 34 (2002) 171-184
53. Wellman P., Ho D., Cepeda-Benito A., Bellinger L., and Nation J. Cocaine-induced hypophagia and hyperlocomotion in rats are attenuated by prazosin. Eur J Pharmacol 455 (2002) 117-126